New York, NY (PRWEB) April 21, 2011
PwC US will sponsor a live webcast at 11 a.m. (ET) Tuesday, April 26, to explore significant changes expected in the pharmaceutical supply chain in the coming years and potential scenarios for how pharmaceutical companies might restructure their supply chain strategy and operating models, depending on unique product and channel portfolios.
The webcast will be led by a panel that includes: Tim Valko, executive director of risk management at Amgen, Wynn Bailey, a principal in PwC's supply chain practice, and Johnathon Marshall, a director in PwC's Pharmaceutical & Life Sciences Advisory Services Group. Ben Come, senior editor at Pharmaceutical Executive magazine, will moderate the discussion.
A basis for the discussion will be PwC's recent report Pharma 2020: Supplying the future. While the industry focuses heavily on issues such as the challenges associated with drug discovery and the regulatory review process, pharmaceutical companies have invested comparatively little effort in updating their manufacturing and distribution operations. PwC finds that most pharmaceutical companies have complex supply chains that are under-utilized, inefficient and ill-equipped to cope with the sort of products, including biologics and specialist therapies, coming down the pipeline. A radical supply chain overhaul is needed.
Webcast attendees will learn about:
- The changing dynamics of supply chains as a strategic function.
- The risks, opportunities and challenges associated with different supply chain models that might emerge in the future.
- Real world leading practices for mitigating risk and mining opportunities in the supply chain to drive business growth.
- Practical ways to apply these learnings to your own organization.
To register for the one-hour webcast, please go to: http://www.pharmexec.com/supplychain.
About PwC's Pharmaceutical and Life Sciences Industry Group
PwC's Pharmaceutical and Life Sciences Industry Group (http://www.pwc.com/pharma or http://www.pwc.com/medtech) provides assurance, tax and advisory services to proprietary, generic and specialty drug manufacturers, medical device and instrumentation suppliers, biotechnology companies, wholesalers, pharmacy benefit managers, contract research organizations, and industry associations. The firm is dedicated to delivering effective solutions to the complex strategic, operational, and financial challenges facing pharmaceutical, biotechnology and medical device companies. Follow PwC Health Industries at http://twitter.com/PwCHealth.
About the PwC Network
PwC firms provide industry-focused assurance, tax and advisory services to enhance value for their clients. More than 161,000 people in 154 countries in firms across the PwC network share their thinking, experience and solutions to develop fresh perspectives and practical advice. See http://www.pwc.com for more information.
© 2011 PwC. All rights reserved. "PwC" and "PwC US" refer to PricewaterhouseCoopers LLP, a Delaware limited liability partnership, which is a member firm of PricewaterhouseCoopers International Limited, each member firm of which is a separate legal entity.
# # #